Noonan syndrome is a condition that is characterized by mildly unusual facial characteristics, short stature, heart defects, bleeding problems, skeletal malformations, and many other signs and symptoms. The prevalence of Noonan syndrome is approx 1 in 1,000 or 0.10% or 293,655 out of 293,655,405 people in USA. The study, of 19 children and 10 adults with Noonan syndrome, found that among the younger children (aged 4-12 years), the incidence of daytime urinary incontinence, nocturnal enuresis, and fecal incontinence was 36.4%, 27.3%, and 11.1%. Treatment for individuals who have Noonan syndrome is based on their particular symptoms. Heart problems are treated in the same way as they are for individuals in the general population.
Growth hormone may be used to treat short stature associated with Noonan syndrome. Physiologic replacement for conditions of growth hormone deficiency. Recurrence risk for parents who do not appear to be affected or who have only some facial features of Noonan syndrome is 5%. Gonadal mosaicism may account for this increase over population risk. Affected individuals have a 50% chance of passing on the disorder with each pregnancy. Alterations in four genes - PTPN11, SOS1, RAF1 and KRAS - have been identified to date.